UCB's Bimekizumab Could Struggle With Saturated Psoriasis Market
Executive Summary
UCB's has reported strong Phase IIb data for its novel psoriasis therapy bimekizumab, but the drug is unlikely to launch before 2022 and is at risk of being redundant on a crowded market.
You may also be interested in...
UCB Promotes 'Underappreciated' Pipeline In FY Results
UCB's pipeline will see advances across multiple therapy areas in 2018, including more emphasis on new epilepsy indications and unmet needs in neurodegenerative diseases like Alzheimer's.
AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount
Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.